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Abstract: The sponge Stylissa carteri is known to produce a number of secondary metabolites
displaying anti-fouling, anti-inflammatory, and anti-cancer activity. However, the anti-viral potential
of metabolites produced by S. carteri has not been extensively explored. In this study, an S. carteri
extract was HPLC fractionated and a cell based assay was used to evaluate the effects of HPLC
fractions on parameters of Human Immunodeficiency Virus (HIV-1) infection and cell viability.
Candidate HIV-1 inhibitory fractions were then analyzed for the presence of potential HIV-1 inhibitory
compounds by mass spectrometry, leading to the identification of three previously characterized
compounds, i.e., debromohymenialdisine (DBH), hymenialdisine (HD), and oroidin. Commercially
available purified versions of these molecules were re-tested to assess their antiviral potential in
greater detail. Specifically, DBH and HD exhibit a 30%–40% inhibition of HIV-1 at 3.1 µM and 13 µM,
respectively; however, both exhibited cytotoxicity. Conversely, oroidin displayed a 50% inhibition of
viral replication at 50 µM with no associated toxicity. Additional experimentation using a biochemical
assay revealed that oroidin inhibited the activity of the HIV-1 Reverse Transcriptase up to 90% at
25 µM. Taken together, the chemical search space was narrowed and previously isolated compounds
with an unexplored anti-viral potential were found. Our results support exploration of marine natural
products for anti-viral drug discovery.
Keywords: Stylissa carteri; marine bioprospecting; HIV-1; reverse transcriptase; Red Sea
1. Introduction
In 2013, there were an estimated 35.3 million people infected and living with HIV [1], and the
number has continued to increase. Drugs currently used as anti-HIV-1 therapeutics fall under five
categories, including inhibitors of viral entry, membrane fusion, the reverse transcriptase, the integrase,
and the protease. Highly active anti-retroviral therapy (HAART) combines drugs from at least two
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of the different classes of the anti-retroviral agents available [2]. Nevertheless, the emergence of
drug resistant retroviruses is still a major issue associated with current anti-HIV-1 drug therapies [3].
Hence, the effectiveness of HIV therapy relies on the discovery and approval of novel therapeutics
that are able to combat the various viral replication phases of HIV.
The first anti-retroviral medicine, azidothymidine (AZT), was approved in 1987 for the treatment
of HIV-1 [4]. This drug terminates DNA strand elongation by the addition of an azide group at
the C-3 of the nucleoside sugar. This modification to the 5-carbon sugar is thought to be inspired
by the nucleoside analogs produced by the sponge Tethya crypta, which possess an arabinose sugar
instead of the deoxyribose sugar required for DNA strand elongation [5]. By substituting the groups
bound to the 21 and 31 carbons of the nucleoside sugar, a number of HIV-1 reverse transcriptase
inhibitors were generated. However, in the past 15 years of clinical trials only five novel natural
product pharmacophores were investigated in clinical trials. The majority of the 133 naturally derived
compounds in clinical trials for the period of 2008–2013 are derivatives of existing pharmacophores
that are already present in existing human medicines. For this same time period, only 2 of the
133 compounds, both derivatives of the cyclosporin A pharmacophore, were investigated as anti-viral
therapeutic candidates in the treatment of the Hepatitis C Virus (HCV) [6]. This reveals that there is a
need for novel anti-viral pharmacophores and their derivatives in clinical trials.
A statistical review by Hu et al. [7] illustrates that bioactivities were assigned to only approximately
25% of the marine natural products reported in the literature from 1985 to 2012. This does not mean
that the remaining 75% do not possess bioactivity; instead, it suggests a discrepancy between the
rate of discovery for marine natural products and the investigation of their associated bioactivities.
A further look into the type of bioactivities reported revealed that 56% of the bioactive compounds
were associated with anti-cancer activity but only 3% with anti-viral activity. Interestingly, in years
where a greater variety of disease targets were screened in order to identify inhibitors, the proportion
of reported bioactivity was the greatest. This illustrates that there is a need to expand marine natural
product screening efforts beyond the detection of anti-cancer activity in order to fully realize the
potential utility of marine secondary metabolites.
In this study, we investigated the anti-viral potential of Stylissa carteri, in the family Scopalinidae,
collected from the Red Sea. S. carteri is known to produce a number of pharmacologically active
brominated pyrrole-2-aminoimidazole alkaloids, which are also produced by sponges from the families
Agelasidae, Axindellidae, Hymeniacidonidae [8]. A review of the literature shows that the chemical
repertoire of Stylissa sp. is well characterized with nearly 100 compounds reported. Among these
compounds, a dimer of oroidin known as sceptrin along with its derivatives debromosceptrin,
dibromosceptrin, and oxysceptrin have been reported to inhibit Herpes Simplex Virus-1 (HSV-1)
and Vesicular Stomatitis Virus (VSV) [9]. This lends support to our aim of identifying molecules with
anti-viral activity from S. carteri. More specific to anti-retroviral activity, another derivative of oroidin,
hymenialdisine (HD), was used experimentally to inhibit Nuclear Factor-kB (NFkB), and subsequently
inhibit transcription from the long terminal repeat (LTR) of the Human Immunodeficiency Virus (HIV)
in vitro [10]. Here, we tested 11 high-performance liquid chromatography (HPLC) fractions obtained
from S. carteri on a well-established cell-based screening system (EASY-HIT, [11]), which evaluates
both anti-HIV activity and cytotoxicity in order to identify compounds with anti-HIV bioactivity from
the Red Sea sponge S. carteri.
2. Results and Discussion
2.1. Biological Activities of Fractions of S. carteri Extracts
S. carteri specimens collected from different coral reefs in the Red Sea were subjected to Solid
Phase Extraction (SPE) under different conditions to generate three desalted fractions enriched for
pharmacologically relevant small organic compounds of moderate polarity. These SPE fractions were
subsequently evaluated for biological activity with an assay system (EASY-HIT; [11]) that co-monitors
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parameters of HIV-infection (i.e., expression of an HIV-dependent reporter gene) and cell viability (i.e.,
metabolic activity of cells). This assay system has been validated for HIV-inhibitor screening and has
been successfully used in the past to evaluate anti-HIV activity of single compounds as well as extracts
from plants and marine algae [11–13].
While all SPE fractions showed biological activities in the EASY-HIT assay, it was not possible to
discriminate between effects on HIV infection and cell viability at this stage. Therefore, we exemplarily
separated SPE fraction 1 (SPE F1) by HPLC into 11 separate fractions and evaluated their biological
activities by EASY-HIT technology. As shown in Figure 1A, HPLC fractions 1, 2, and 6 strongly
diminished expression of the HIV-reporter gene in the reporter cells, while the other HPLC fractions
showed no or weaker inhibitory effects on the HIV infection parameter. HPLC fractions 2 and 6 also
showed moderate effects on cell viability. Effects of HPLC fraction 1 on cell viability were stronger,
resulting in elimination of HPLC fraction 1 for further analysis.
Figure 1. (A) HIV infection of RIC cells: Three biological replicates of 11 HPLC fractions (approx.
20 µg/mL each) generated from S. carteri SPE F1 were tested for the ability to inhibit HIV-1 replication
in the EASY-HIT assay; (B) the cell viability of the infected LC5-RIC reporter cells treated with the
three biological replicates of HPLC fraction 1–11 generated from S. carteri SPE F1 were assessed by
the Microculture Tetrazolium Test (MTT). The error bars represent one standard deviation from the
mean. p values from unpaired t-tests between the neighboring HPLC fractions are as follows for %
infection and % cell viability: p = 0.43, 0.09 (HPLC 1:2), p = 0.0005, 0.0004 (HPLC 2:3), p = 0.8289, 0.8790
(HPLC 3:4), p = 0.1125, 0.1500 (HPLC 4:5), p = 0.0315, 0.4033 (HPLC 5:6), p = 0.2341, 0.0209, (HPLC 6:7),
p = 0.3528, 0.3941 (HPLC 7:8), p = 0.3464, 0.5351 (HPLC 8:9), p = 0.7839, 0.0413 (HPLC 9:10), p = 0.9877,
0.0892(HPLC 10:11).
2.2. Identification of HIV-1 Candidate Inhibitors in HPLC Fractions 2 and 6
To further evaluate potential HIV-inhibitory activity of S. carteri, we used LC-MS analysis
to determine compounds common to HPLC fractions 2 and 6 as the most likely candidates
for antiviral compounds (Figure 2A). The most prominent compounds common to both spectra
included: debromohymenialdisine (DBH, m/z [M + H]+ 246, C11H12N5O2), hymenialdisine
(HD, 10Z-hymenialdisine (m/z [M + H]+ 324, C11H11BrN5O2), and oroidin (m/z [M + H]+ 389,
C11H12Br2N5O) (Figure 2B).
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Figure 2. (A) overlay of LC-MS chromatograms for HPLC fractions 2 (black) and 6 (red) generated
from S. carteri SPE fraction 1; and (B) a spectrum of the m/z values common to both HPLC fraction 2
and 6 between minutes 17–40. The three known compounds debromohymenialdisine (m/z [M + H]+
246, C11H12N5O2), 10Z-hymenialdisine (m/z [M + H]+ 324, C11H11BrN5O2), oroidin (m/z [M + H]+
389, C11H12Br2N5O) have the greatest relative abundance among the shared compounds common to
both HPLC fractions 2 and 6.
2.3. Three HIV-1 Candidate Inhibitors Hymenialdisine, Debromohymenialdisine, and Oroidin from S. carteri
Inhibit HIV-1 Replication to Varying Degrees
Oroidin [14], HD and DBH [15,16], isolated and characterized in 1973 and the 1980s, respectively,
have since been synthesized and are available for purchase. The single compounds were purchased
and evaluated in the EASY-HIT assay for their ability to inhibit HIV-1 replication. The pure compounds
were also used as standards and their presence was confirmed in the SPE F1 from the Red Sea S. carteri
specimen collected in this study. Tandem mass spectrometry showed a similar retention time and
fragmentation pattern for the commercial DBH, HD, and oroidin compounds and their corresponding
compounds present in S. carteri SPE F1 (Figures S1 and S2). The DHB treatment inhibited HIV-1
infection down to 30% of untreated controls at a concentration of 13 µM without affecting cell viability
(Figure 3A,B). The specific anti-viral effect was even stronger for HD, which clearly inhibited HIV
infection to <40% at a concentration of 3.1 µM without affecting cell viability. Oroidin showed the
weakest antiviral activity, reducing HIV-1 infection to 50% at a concentration of 50 µM, and proved to
be nontoxic for cells at all tested concentrations (Figure 3A,B).
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Figure 3. (A) the single compounds DBH, HD, and oroidin from S. carteri are tested for the ability to
inhibit HIV-1 replication in HIV-1 permissible LC5-RIC reporter cells in the EASY-HIT assay; (B) cell
viability of the infected LC5-RIC reporter cells treated with the single compounds DBH, HD, and
oroidin from S. carteri was assessed by the MTT assay. The error bars represent one standard deviation
from the mean. The p values between the six tested concentrations of each of the three compounds
are reported first for the % infection and then % viability graph as follows: debromohymenialdisine
p = 0.0001, p = 0.0001; hymenialdisine, p = 0.0001, p = 0.0001; oroidin, p = 0.0001, p = 0.0001.
2.4. Oroidin from S. carteri Inhibits the HIV-1 Reverse Transcriptase (RT) in a Biochemical Assay
The procured purified preparations of DBH, HD, and oroidin were screened in an HIV-1 RT
biochemical assay. Interestingly, DBH and HD did not show anti-HIV-1 RT activity. In contrast, oroidin
was capable of a 90% inhibition of the HIV-1 RT enzyme at concentrations greater than 25 µM (Figure 4).
In the cell-based assay used here, oroidin was shown to reduce HIV-1 replication up to 50% when
applied at a 50 µM concentration and is non-cytotoxic at all tested concentrations. This suggests that
the mechanism of inhibition of oroidin as an HIV-1 RT inhibitor might be hindered by its poor ability
to be absorbed by a living cell. Thus, improvements in oroidin as a prospective scaffold for HIV-1
inhibition would require additional medical chemistry modification. Our findings are in contrast to a
previous study where oroidin was obtained as a by-product and was tested for its ability to inhibit HIV
replication. In that study, oroidin was found inactive but also non-cytotoxic. The previous study [17]
did not detail the concentrations used in the assay; however, their negative result may have been due
to testing at too low a concentration of oroidin to observe activity in a cell-based assay.
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Figure 4. Inhibitory activity of DBH, HD and oroidin from S. carteri on the HIV-1 RT in a biochemical
assay. The error bars represent one standard deviation from the mean. The p values are reported for %
activity of the RT as follows: debromohymenialdisine, p = 0.0023; hymenialdisine, p = 0.169; oroidin,
p = 0.0001.
Many of the pharmacologically active brominated pyrrole-2-aminoimidazole alkaloids from
S. carteri are assumed to be derivatives of the building block oroidin [18]. In this study, oroidin was
found to be capable of inhibiting HIV-1 replication without causing cytotoxicity. HD, a derivative
of oroidin, was also found to be capable of inhibiting HIV-1 replication; however, cytotoxicity was
observed at concentrations greater than 3.1 µM. This could be due to the ability of HD to bind Nuclear
Factor-κB (NFκB), which is crucial for a number of cellular processes as well as the ability to induce
the process of transcription from the HIV-1 long terminal repeat (LTR). Similarly, DBH gives rise to
cytotoxicity at concentrations greater than 13 µM, a value greater than that observed for HD, perhaps
on account of its lack of the electronegative bromine atom. Furthermore, HD along with DBH have
been reported to compete with ATP for binding to a number of cyclin-dependent kinases (CDK),
including CDK2 [19], where the ability to inhibit CDK2 has been shown to decrease the transcription of
the HIV-1 virus [18,20]. Additionally, DBH and HD have been reported to abrogate the G2-checkpoint
of the cell cycle [21]. A G2 arrest is thought to pose a replicative advantage for the virus, as the HIV-1
LTR is most active during this phase [22]. This suggests that DBH and HD may also be able to relieve
the cell cycle arrest that supports HIV pathogenesis; however, a prolonged arrest can also lead to
apoptosis and result in cytotoxicity. NFκB, CDK2, and G2-checkpoint interference are three possible
mechanisms of action to explain the inhibition observed from HD and DBH in this study; however,
the inhibition of such ubiquitous cellular proteins and processes could also explain the cytotoxicity
associated with HD and DBH as well as that observed for the parent SPE F1 mixture and in HPLC
fractions 1, 2 and 6. From this study, it was observed that oroidin is directly acting to inhibit the
retroviral Reverse Transcriptase, while DBH and HD do not affect this enzyme. It remains to be
determined whether DBH and HD possess anti-viral activity at other steps of the virus life cycle that
were not measured in this study. Similarly, future work should assess whether oroidin only affects the
reverse transcriptase or whether other enzymes or life cycle steps are affected.
3. Experimental Section
3.1. S. carteri Specimen Collection and Sample Fractionation
Three biological replicates of S. carteri (described by Denny 1889, identified by Dr. N.J. de Voogd)
were collected using gardening shears from three coral reef locations: C26 from Inner Fsar, West
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(22˝13.974N, 39˝01.760E), C14 from Inner Fsar, East (22˝13.850N, 39˝02.216E), and D5 from Al Fahal,
East (22˝15.119N, 38˝57.761E), using SCUBA at approximately 12 m depth. The specimens were
washed with 1% Phosphate Buffered Saline (PBS) on the boat then wrapped in foil and placed on
ice then stored at ´80 ˝C until processing. Small sponge specimens of 4–10 g of sponge specimen
were ground using a mortar and pestle and then extracted with 15 mL of methanol overnight at 4 ˝C.
The following day, the methanol extract was dried onto 150 mg of Diaion HP20SS beads in a CentriVap
complete vacuum concentrator (Labconco, Kansas City, MO, USA) on low and the beads were then
loaded into a 25 mL Flash Cartridge (Sorbtech, Norcross, GA, USA) with 0.795 diameter Frits (Sorbtech),
desalted with deionized water (15 mL, FW1, FW2) and then eluted with 15 mL of 25% IPA/H2O
(SPE fraction 1) [23]. The solvents was centrifugally evaporated in a CentriVap complete vacuum
concentrator (Labconco, Kansas City, MO, USA) and re-dissolved in 2 mL HPLC grade methanol
(Sigma Aldrich, Saint Louis, MO, USA) for injection into the HPLC.
3.1.1. Analytical Chemistry of Bioactive S. carteri Fractions
The HPLC fractionation was peak-based and was carried out with a 50 µL (approximately 500 µg
of material, dry weight) injection of material and a flow rate of 0.400 mL/min using a ZORBAX Eclipse
XDB-C18 LC Column, 4.6 mm, 150 mm, 5 µm (Agilent Technologies, Santa Clara, CA, USA), and
the gradient reported in Table S1. SPE fraction 1 and HPLC fractions 2 and 6 were analyzed on the
Thermo LTQ Orbitrap with 10 µL of material and a flow rate of 0.800 mL/min using a ZORBAX Eclipse
XDB-C18 LC Column, 4.6 mm, 150 mm, 5 µm and the gradient reported in Table S2. Analysis and
prediction of elemental formulas were carried out with Xcalibur 2.1 software (Thermo Scientific,
Waltham, MA, USA). MS/MS was preformed using a collision-induced dissociation (CID) of 30 eV on
both the parent SPE fraction 1 as well as the three standards of DBH, HD and oroidin and targeted
m/z 246.09, 324.00, and 389.93, respectively.
3.1.2. Single Compounds from Bioactive S. carteri Fractions
The individual synthesized compounds debromohymenialdisine (Lot: L20314, Enzo Life Sciences,
Farmindale, NY, USA), 10Z-hymenialdisine (Lot: L27315, Enzo Life Sciences) and oroidin (Lot: L26427,
Enzo Life Sciences) (Figure S3) were ordered screened on the EASY-HIT assay and the HIV-1 RT
biochemical assay at molarities below 100 µM in order to assess their ability inhibit HIV-1 replication.
Statistical significances were determined using one-way ANOVA.
3.2. Human Immunodeficiency Virus, Full Virus Screening (EASY-HIT)
The EASY-HIT assay [11] is based on HIV-1 susceptible reporter cells (LC5-RIC) that contain
a stably integrated fluorescent reporter gene that is activated upon successful HIV-1 infection
and expression of the early viral proteins Rev and Tat. LC5-RIC were seeded into 96-well plates
(µCLEAR-Plate Black; Greiner Bio-One, Kremsmuenster, Germany) using only the 60 inner wells
to avoid variations in the culture conditions in the outer wells. Cells were seeded at a density of
10,000 cells per well 24 h prior to infection. SPE fractions for the biological replicates C26, C14 and
D5, were tested in a serial 1:2-dilution with a maximum of 3% methanol or approximately 75 µg/mL
for the S. carteri fraction 1 mixture on the EASY-HIT assay [11]. For the HPLC fractions, SPE fraction
1 HPLC fractions 1–11, were tested on the EASY-HIT assay for biological replicates C26, C14 and
D5. The authentic samples of HD, DBH, and oroidin were screened at 3.1 µM, 6.25 µM, 12.5 µM,
25 µM, and 50 µM. All samples were tested in triplicate. After compound addition, LC5-RIC cells
were infected by adding 20 µL of HIV-1 inoculum (approx. 28.8 ng of p24 for HIV-1LAI derived from
HEK 293T cells) to each well of the plate. Cells were incubated at standard cell culture conditions
for 48 h after infection and were subsequently assayed for reporter expression and cell viability.
Reporter expression was determined by measuring the total fluorescent signal intensity of each culture
with a fluorescence microplate reader (Fluoroskan Ascent; ThermoFisher, Schwerte, Germany) at an
excitation filter wavelength of 544 nm and an emission filter wavelength of 590 nm or with a Tecan
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infinite M200 (Tecan, Crailsheim, Germany) at the monochromator wavelengths 552 nm for excitation
and 596 for emission. Statistical significances were determined using unpaired t-tests for neighboring
HPLC fractions.
MTT Cell Proliferation Assay
The colorimetric assay MTT was used in order to assess the viability and activity of LC5-RIC cells
exposed to the unknown sponge mixtures, SPE fraction 1 and HPLC fractions 1–11, for three biological
replicates. This cell viability assay provides a visualization of the process where mitochondrial enzymes
reduce the yellow MTT to purple formazan (American Type Culture Collection (ATCC), MTT cell
proliferation assay). After reading the HIV reporter expression, cultures were incubated with 100 µL
of MTT solution (0.5 mg of MTT; Sigma, Taufkirchen, Germany) in 100 µL of culture medium for 2 h.
MTT solution was removed and 100 µL of lysis solution (10% (w/v) SDS and 0.6% (v/v) acetic acid in
dimethyl sulfoxide (DMSO)) was added. The formazan concentrations of the test compounds and the
uninfected control cultures were determined by an ELISA plate reader (Tecan Infinite M200, Tecan
Germany GmbH, Crailsheim, Germany) and scanned with a test wavelength of 570 nm and a reference
wavelength of 630 nm. Statistical significances were determined using one-way ANOVA.
3.3. Human Immunodeficiency Virus, Reverse Transcriptase Biochemical Test
The HIV-1 reverse transcriptase inhibition assay was carried out using the commercial kit
EnzChek® Reverse Transcriptase Assay (Invitrogen, San Jose, CA, USA). The reverse transcriptase is a
heterodimer with the p66 and the p51 subunits with RNase H activity located in the last 15KDa of the
p66 HIV Reverse transcriptase (Calbiochem, Merck-Millipore, Billerica, MA, USA). Polymerase activity
was assessed by its ability to produce RNA-DNA heteroduplexes from a mixture of a long poly (A)
template, an oligo dT primer and dTTP which is then detected by PicoGreen® dsDNA quantitation
reagent. The single compound and controls were performed in triplicated in a 384-well plate format,
each with a total reaction mixture of 50 µL. To begin, the poly (A) template was annealed to the oligo dT
primer for one hour, then diluted 200 fold in polymerization buffer. Reverse transcriptase (1.2 µL) was
added per 300 reactions. This mixture was kept on ice and aliquoted to each well with test compounds.
The reaction was incubated at room temperature for one hour and then 2 µL of 50 nM EDTA was added
to stop the reaction. The RNA-DNA heteroduplex was labeled with PicoGreen and incubated for
5 min and then detected with the use of a SpectraMax® Paradigm® Multi-mode Microplate Detection
Platform (Molecular Devices, Sunnyvale, CA, USA) by scanning at 480 nm excitation wavelength and
520 nm emission wavelength. The authentic standards of HD, DBH, and oroidin were screened at
3.1 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, and 100 µM. Statistical significances were determined using
a one-way ANOVA.
4. Conclusions
S. carteri is a sponge with wide geographical distribution that has been shown to produce bioactive
secondary metabolites, some of which are also present in members of three other sponge families.
The three metabolites detected in this study, DBH, HD and oroidin, were characterized 30–40 years
ago. This investigation revealed that these compounds are able to inhibit HIV-1 replication, and could
serve as starting scaffolds for further investigation. The long time lag between the original discovery
of these compounds and this report on their anti-retroviral activity accentuates the unevenness of the
screening efforts of natural products and the need for diversification in assay targets. The broader
implication of this observation is that the anti-viral pharmacophore potential of many marine natural
products might currently be overlooked. In the future, anti-viral screening efforts similar to this one
could reveal new marine-derived agents useful in combating these devastating viral diseases.
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